Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-α converting enzyme inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 10, 2003, Pages 1811-1823

  Cherney, Robert J ^a   Duan, James J W ^a   Voss, Matthew E ^a   Chen, Lihua ^a   Wang, Li ^a   Meyer, Dayton T ^a   Wasserman, Zelda R ^a   Hardman, Karl D ^a   Liu, Rui Qin ^a   Covington, Maryanne B ^a   Qian, Mingxin ^a   Mandlekar, Sandhya ^a   Christ, David D ^a   Trzaskos, James M ^a   Newton, Robert C ^a   Magolda, Ronald L ^a   Wexler, Ruth R ^a   Decicco, Carl P ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIADIAZEPINE HYDROXAMATE DERIVATIVE; CGS 27023A; DIAZEPINE DERIVATIVE; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; N HYDROXY 2 (7 BENZYLOXY 2,3,4,5 TETRAHYDROBENZO[1,2,5 F]THIADIAZEPINE 1,1 DIOXIDE) 4 METHYLPENTANAMIDE; N HYDROXY 2 [7 (3 NITROPHENOXY) 2,3,4,5 TETRAHYDROBENZO[1,2,5 F]THIADIAZEPINE 1,1 DIOXIDE]PROPANAMIDE; N HYDROXY 2 [7 (3,5 DIETHOXYBENZYLOXY) 2,3,4,5 TETRAHYDROBENZO[1,2,5 F]THIADIAZEPINE 1,1 DIOXIDE] 4 METHOXYCARBONYLPENTANAMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; CELL ASSAY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION; SWINE;

ADAM PROTEINS; ANIMALS; BENZODIAZEPINONES; BLOOD PROTEINS; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKOCYTES, MONONUCLEAR; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; THIAZEPINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0012727923     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020475w     Document Type: Article

References (35)

1. Aggarwal, B. B.; Natarajan, K. Tumor necrosis factors: developments during the last decade. Eur. Cytokine Network 1996, 7, 93-124.
2. Feldmann, M.; Brennan, F. M.; Williams, R. O.; Cope, A. P.; Gibbons, D. L.; Katsikis, P. D.; Maini, R. N. Evaluation of the role of cytokines in autoimmune disease: The importance of TNFα in rheumatoid arthritis. Prog. Growth Factor Res. 1992, 4, 247-255.
3. Van Assche, G.; Rutgeerts, P. Anti-TNF agents in Crohn's disease. Expert Opin. Invest. Drugs 2000, 9, 103-111.
4. Kristensen, M.; Chu, C. Q.; Eedy, D. J.; Feldmann, M.; Brennan, F. M.; Breathnach, S. M. Localization of tumor necrosis factor-alpha (TNF-α) and its receptors in normal and psoriatic skin: Epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin. Exp. Immunol. 1993, 94, 354-362.
5. Black, R. A.; White, J. M. ADAMs: focus on the protease domain. Curr. Opin. Cell Biol. 1998, 10, 654-659.
6. Moss, M. L.; White, J. M.; Lambert, M. H.; Andrews, R. C. TACE and other ADAM proteases as targets for drug discovery. Drug Discovery Today 2001, 6, 417-426.
7. Stocker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F.-X.; McKay, D. B.; Bode, W. The metzincins - Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995, 4, 823-840.
8. Hooper, N. M. Families of zinc metalloproteases. FEBS Lett. 1994, 354, 1-6.
9. Mohler, K. M.; Sleath, P. R.; Fitzner, J. N.; Cerretti, D. P.; Alderson, M.; Kerwar, S. S.; Dauphine, S. T.; Otten-Evans, C.; Greenstreet, T.; Weerawarna, K.; Kronheim, S. R.; Petersen, M.; Gerhart, M.; Kozlosky, C. J.; March, C. J.; Black, R. A. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 1994, 370, 218-220.
10. McGeehan, G. M.; Becherer, J. D.; Bast, R. C., Jr.; Boyer, C. M.; Champion, B.; Connolly, K. M.; Conway, J. G.; Furdon, P.; Karp, S.; Kidao, S.; McElory, A. B.; Nichols, J.; Pryzwansky, K. M.; Schoenen, F.; Sekut, L.; Truesdale, A.; Verghese, M.; Warner, J.; Ways, J. P. Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994, 370, 558-561.
11. Gearing, A. J. H.; Beckett, P.; Christodoulou, M.; Churchill, M.; Clements, J.; Davidson, A. H.; Drummond, A. H.; Galloway, W. A.; Gilbert, R.; Gordon, J. L.; Leber, T. M.; Mangan, M.; Miller, K.; Nayee, P.; Owen, K.; Patel, S.; Thomas, W.; Wells, G.; Wood, L. M.; Woolley, K. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 1994, 370, 555-557.
12. Black, R. A.; Rauch, C. T.; Kozlosky, C. J.; Peschon, J. J.; Slack, J. L.; Wolfson, M. F.; Castner, B. J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; March, C. J.; Cerretti, D. P. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature 1997, 385, 729-733.
13. Moss, M. L.; Jin, S.-L. C.; Milla, M. E.; Burkhart, W.; Carter, H. L.; Chen, W.-J.; Clay, W. C.; Didsbury, J. R.; Hassler, D.; Hoffman, C. R.; Kost, T. A.; Lambert, M. H.; Leesnitzer, M. A.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L. K.; Schoenen, F.; Seaton, T.; Su, J.-L.; Warner, J.; Willard, D.; Becherer, J. D. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-α. Nature 1997, 385, 733-736.
14. Maskos, K.; Fernandez-Catalan, C.; Huber, R.; Bourenkov, G. P.; Bartunik, H.; Ellestad, G. A.; Reddy, P.; Wolfson, M. F.; Rauch, C. T.; Castner, B. J.; Davis, R.; Clarke, H. R. G.; Petersen, M.; Fitzner, J. N.; Cerretti, D. P.; March, C. J.; Paxton, R. J.; Black, R. A.; Bode, W. Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3408-3412.
15. Nelson, F. C.; Zask, A. The therapeutic potential of small molecule TACE inhibitors. Expert Opin. Invest. Drugs 1999, 8, 383-392.
16. Newton, R. C.; Decicco, C. P. Therapeutic potential and strategies for inhibiting tumor necrosis factor-α. J. Med. Chem. 1999, 42, 2295-2314.
17. Moreland, L. W.; Baumgartner, S. W.; Schiff, M. H.; Tindall, E. A.; Fleischmann, R. M.; Weaver, A. L.; Ettlinger, R. E.; Cohen, S.; Koopman, W. J.; Mohler, K.; Widmer, M. B.; Blosch, C. M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997, 337, 141-147.
18. Elliott, M. J.; Maini, R. N.; Feldmann, M.; Kalden, J. R.; Antoni, C.; Smolen, J. S.; Leeb, B.; Breedveld, F. C.; Macfarlane, J. D.; Bijl, H.; Woody, J. N. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344, 1105-1110.
19. Elliott, M. J.; Maini, R. N.; Feldmann, M.; Long-Fox, A.; Charles, P.; Bijl, H.; Woody, J. N. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344, 1125-1127.
20. Keating, G. M.; Perry, C. M. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 2002, 16, 111-148.
21. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.-I.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532.
22. Fukuyama, T.; Jow, C.-K.; Cheung, M. 2- and 4-Nitrobenzenesulfonamides: exceptionally versatile means for preparation of secondary amines and protection of amines. Tetrahedron Lett. 1995, 36, 6373-6374.
23. Chan, D. M. T.; Monaco, K. L.; Wang, R.-P.; Winters, M. P. New N- and O-arylation with phenylboronic acids and cupric acetate. Tetrahedron Lett. 1998, 39, 2933-2936.
24. Evans, D. A.; Katz, J. L.; West, T. R. Synthesis of diaryl ethers through the copper-promoted arylation of phenols with arylboronic acids. An expedient synthesis of thyroxine. Tetrahedron Lett. 1998, 39, 2937-2940.
25. Xue, C.-B.; Voss, M. E.; Nelson, D. J.; Duan, J. J. W.; Cherney, R. J.; Jacobson, I. C.; He, X.; Roderick, J.; Chen, L.; Corbett, R. L.; Wang, L.; Meyer, D. T.; Kennedy, K.; DeGrado, W. F.; Hardman, K. D.; Teleha, C. A.; Jaffee, B. D.; Liu, R.-Q.; Copeland, R. A.; Covington, M. B.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Magolda, R. L.; Wexler, R. R.; Decicco, C. P. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor-α release in vitro and in vivo. J. Med. Chem. 2001, 44, 2636-2660.
26. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776.
27. Drummond, A. H.; Beckett, P.; Brown, P. D.; Bone, E. A.; Davidson, A. H.; Galloway, W. A.; Gearing, A. J. H.; Huxley, P.; Laber, D.; McCourt, M.; Whittaker, M.; Wood, L. M.; Wright, A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N. Y. Acad. Sci. 1999, 878, 228-235.
28. Porter, J. R.; Beeley, N. R. A.; Boyce, B.; Mason, B.; Millican, A.; Millar, K.; Leonard, J.; Morphy, J. R.; O'Connell, J. P. Potent and selective inhibitors of gelatinase-A. 1. Hydroxamic acid derivatives. Bioorg. Med. Chem. Lett. 1994, 4, 2741-2746.
29. Lovejoy, B.; Cleasby, A.; Hassell, A. M.; Longley, K.; Luther, M. A.; Weigl, D.; McGeehan, G.; McElroy, A. B.; Drewry, D.; Lambert, M. H.; Jordan, S. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994, 263, 375-377.
30. Miller, A.; Askew, M.; Beckett, R. P.; Bellamy, C. L.; Bone, E. A.; Coates, R. E.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Martin, F. M.; Saroglou, L.; Thompson, A. J.; Dijk, S. E.; Whittaker, M. Inhibition of matrix metalloproteinases: an examination of the S1′ pocket. Bioorg. Med. Chem. Lett. 1997, 7, 193-198.
31. Wasserman, Z. R.; Duan, J. J.-W.; Voss, M. E.; Xue, C.-B.; Cherney, R. J.; Nelson, D. J.; Hardman, K. D.; Decicco, C. P. Identification of a Selectivity Determinant for Inhibition of Tumor Necrosis Factor-α Converting Enzyme (TACE) by Comparative Modeling. Chemistry & Biology 2003, 10, 1-20.
32. Duan, J. J.-W.; Chen, L.; Wasserman, Z. R.; Lu, Z.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Hardman, K. D.; Magolda, R. L.; Newton, R. C.; Christ, D. D.; Wexler, R. R.; Decicco, C. P. Discovery of γ-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor-α converting enzyme: design, synthesis and structure-activity relationships. J. Med. Chem. 2002, 45, 4954-4957.
33. Trifilieff, A.; Walker, C.; Keller, T.; Kottirsch, G.; Neumann, U. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br. J. Pharmacol. 2002, 135, 1655-1664.
34. Solomon, K. A.; Covington, M. B.; Decicco, C. P.; Newton, R. C. The fate of pro-TNF-α following inhibition of metalloprotease-dependent processing to soluble TNF-α in human monocytes. J. Immunol. 1997, 159, 4524-4531.
35. Schlondorff, J.; Becherer, J. D.; Blobel, C. P. Intracellular maturation and localization of the tumor necrosis factor α convertase (TACE). Biochem. J. 2000, 347, 131-138.